Biogen dumps doubtful Alzheimer’s drug after profit-killing FDA scandal
Enlarge / The outside of the headquarters of biotechnology firm Biogen in Cambridge, Massachusetts. (credit score: Getty | Boston Globe) Biotechnology firm Biogen is abandoning Aduhelm, its questionable Alzheimer’s drug that has floundered available on the market since its scandal-plagued